SANTA CLARA, Calif., Dec. 13, 2011
Agilent Technologies Inc. (NYSE: A) today announced that Yale University has made a major purchase of Agilent bioanalytical systems to support six research institutes it is establishing at its new West Campus. Financial details were not disclosed.
Yale and Agilent officials also say they are discussing entering into a scientific collaboration that would encompass integrative biology, synthetic biology and quantitative proteomics to gain new insights into disease mechanisms.
"Agilent provides sophisticated analytical instrumentation across a broad spectrum of technologies," said Christopher D. Incarvito, Ph.D., director of research technology at Yale's West Campus. "This will be of tremendous value to our chemistry, biology and genetics researchers. This initial investment represents a substantial leap forward, and will accelerate our ongoing and future research endeavors at West Campus."
"Advancing our understanding of life-science systems requires collaborative research across multiple platforms," said Darlene Solomon, Ph.D., Agilent chief technology officer. "Agilent solutions help researchers integrate different types of biological data in pursuit of medical breakthroughs, and the Yale group shares our vision."
The purchase includes three nuclear magnetic resonance spectroscopy systems; a 6120 single quadrupole and a 6490 triple quadrupole LC/MS system; a 7890A GC/MS system; a BioCel 900 automation system; and 660-FTIR and 300-UV-Vis spectroscopy systems.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.
# # #